Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the correction or maintenance treatment of anemia in subjects with incident Dialysis Dependent Chronic kidney disease (DD-CKD) (INNO2VATE – CORRECTION/CONVERSION) (Protocol # AKB-6548-CI-0016)

Study Details

This is a multicenter, randomized, open-label, active-controlled Phase 3 study of the efficacy and safety of vadadustat versus darbepoetin alfa for the correction or maintenance treatment in subjects with anemia secondary to CKD who have recently initiated dialysis treatment for end-stage renal disease

Learn More NCT number

Principal Investigators

  • Eric Brown, MD
Maryanne Ducey, DC, RN at 203-358-8879